Archives : September 2016

The Quebec Parkison Network will Participare in the 2016 Parkinson’s Journey


This Sunday, the Quebec Parkinson Network will participate in the biggest annual fundraising event for Parkinson’s disease in Quebec for the second year in a row. Thousands of people participate in this yearly event and take on the challenge to move together to support those living with Parkinson’s disease. 

Location: Lafontaine Park

Time: Sunday, 11th of September at 10 am

Please find all the details at the link below, and join us!

$213 Million Donated to Montreal Research Institutions


Four research institutions in Montreal have received a grant for a huge total of $213 million. McGill University, Université de Montréal, HEC Montréal, and Polytechnique Montréal will share the money and all embark on new research projects.

l’UdeM, HEC Montréal and Polytechnique Montréal will work on IVADO, a new multidisciplinary Big Data research centre, while McGill will put its share to work on its “Healthy Brain, Healthy Life”  neuroscience research initiative.

Read on, link in French, here:

Vaccine for Parkinson’s Reports Positive Results from Boost Study


The Michael J Fox Foundation reports that a new, second-round vaccine is being successfully tested in Austria. The researchers will present their findings at the World Parkinson Congress in Portland, OR later this month.

The foundation’s website reports: “The “boost” study builds on a first clinical trial, also funded by MJFF, where 24 participants with early-stage Parkinson’s received four doses of PD01A. That trial proved the treatment was safe and showed that half of the participants created alpha-synuclein antibodies. Within a year, however, each of the “responders” saw their levels of alpha-synuclein antibodies decline.

This follow-up trial gave each participant one more dose a year later to see if a “boost” would be safe and would raise antibody levels again. AFFiRiS reported today that the trial was safe; all 28 participants (22 from the first trial and six other people with PD) completed the study. In addition, more volunteers (86 percent) saw an antibody response. All responders from the first trial responded again, and some who did not respond in the first trial produced antibodies with the boost.

“This showed that the body is not desensitized to the vaccine and can produce alpha-synuclein antibodies again,” said Kuldip Dave, PhD, MJFF director of research programs who directs our alpha-synuclein portfolio. “And that you don’t have only one opportunity for treatment — that if you don’t produce antibodies with a first round of vaccine, you may with follow-up.” ”

Read on here: